<DOC>
	<DOCNO>NCT02758912</DOCNO>
	<brief_summary>The objective study evaluate long-term plasma urine pharmacokinetic parameter Cardionat® , capsule 250 mg , use healthy athlete volunteer . The study consist four step : - Step 1 . Screening - select healthy volunteer inclusion study ; - Step 2 . Assignment one study group , prescription study drug ; - Step 3 . Samples collection pharmacokinetic analysis ; - Step 4 . Evaluation pharmacokinetic data .</brief_summary>
	<brief_title>Clinical Study Medicinal Product Cardionat® Using Health Athlete Volunteers</brief_title>
	<detailed_description>Cardionat structural analogue gamma-butyrobetaine - substance every cell human body . Under extra strain condition cardionat restores balance oxygen delivery cell cellular oxygen demand . Cardionat clear intracellular accumulation toxic metabolic product , protect damage ; also general tonic effect . As result use body acquire ability withstand stress quickly restore energy reserve . Because property cardionat use treat variety disorder cardiovascular system , disorder blood supply brain , well improve physical mental performance . Synthesis gamma-butyrobetaine , vasodilating property , highly increase result reduce concentration carnitine . In case acute ischemic myocardial injury cardionat slow formation necrotic area , shorten rehabilitation period . In heart failure increase myocardial contractility , increase exercise tolerance , reduce frequency angina attack . In acute chronic ischemic cerebrovascular disorder improve blood circulation ischemic area ; promote blood redistribution increase supply ischemic area . It effective case vascular dystrophic pathology ocular fundus . The drug eliminate functional disturbance nervous system patient chronic alcoholism abstinence syndrome . Pharmacokinetics After oral administration , drug rapidly absorb . Bioavailability 78 % . The maximum plasma concentration reach 1-2 hour oral ingestion . The drug metabolize body formation two major metabolite , excrete kidney . The half-life oral intake dose-dependent , usually 3 6 hour . Indications use : As part combination treatment coronary heart disease ( angina , myocardial infarction ) , congestive heart failure dyshormonal cardiomyopathy , well part combination treatment acute chronic cerebrovascular disorder ( stroke cerebrovascular insufficiency ) . Reduced working capacity ; physical stress , include physical stress athlete . Abstinence syndrome chronic alcohol abuser ( combination specific alcohol abuse therapy ) . In study , volunteer receive study medication form oral capsule 250 mg . The study drug apply follow : - Group 1 : intake study medication capsule orally dose 1 g per day 3 week - 14 volunteer ( 7 male 7 female ) ; - Group 2 : intake study medication capsule dose 2 g per day 3 week - 14 volunteer ( 7 male 7 female ) .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Angina Pectoris</mesh_term>
	<mesh_term>Stroke</mesh_term>
	<criteria>1 . Healthy volunteer sex age 18 35 year old , caucasians ; 2 . At least 1st sport category among adult ; 3 . Verified diagnosis `` healthy '' accord detailed medical history , accord standard clinical , laboratory instrumental method examination ; 4 . BMI 18.5 30 kg / m2 ; 5 . Signed Volunteer information sheet Informed consent form ; 6 . Agreement volunteer use adequate method contraception ( contraceptive reliability 90 % : cervical cap spermicide , diaphragm spermicide , condom , intrauterine device ) , total abstinence sexual activity period study : For woman whole period 30 day prior sign Volunteer 's information sheet Informed consent form 30 day completion study participation ; period date signing Informed consent 30 day completion study participation barrier method contraception use , main method ; For men whole period sign Volunteer 's information sheet Informed consent form completion study barrier method contraception use . Non inclusion criterion : 1 . Allergy past ; 2 . Drug intolerance , hypersensitivity component study drug ; 3 . Chronic cardiovascular , bronchopulmonary , endocrine nervous system disease ( include psychiatric disorder ) , diseases gastrointestinal tract ( GIT ) , liver , kidney , blood disorder , surgical intervention gastrointestinal tract ( except appendectomy ) ; 4 . Fructose intolerance , glucosegalactose malabsorption sucraseisomaltase insufficiency ; 5 . Poor develop superficial vein forearm ; 6 . Acute infectious , noninfectious allergic disease le 4 week prior Visit 1 ( screen ) ; 7 . Positive blood test HIV , syphilis , hepatitis B C ; 8 . Intake 10 unit alcohol per week ( 1 unit alcohol equivalent 1/2 liter beer , 200 ml wine 50 ml spiritus ) alcoholism , drug addiction drug abuse past ; 9 . Smoking 10 cigarette per day ; 10 . Systolic blood pressure measure `` sit '' position 100 mm Hg 130 mm Hg and/or diastolic blood pressure 60 mm Hg 90 mm Hg ; 11 . Heart rate 40 beat / min ; 12 . Any deviation normal range result clinical laboratory test ( complete blood count , urinalysis , blood chemistry ) instrumental test ( ECG ) ; 13 . Intake medicine , include supplement , agree study doctor ; 14 . Blood donation : 049 ml 0 day prior Visit 1 ( screen ) ; 50449 ml less 30 day prior Visit 1 ; 450800 ml less 60 day prior Visit 1 ; 800 ml decision Chief Investigator , period time prior visit 1 60 day ; 15 . Plasmapheresis le 14 day prior Visit 1 ; 16 . Participation competition , dope test require , participate clinical trial ( within 6 ± 2 month date inclusion study Visit 1 ( Screening ) ) ; 17 . Participation study another medicinal product medical device le 3 month prior study ; 18 . Volunteer 's inability unwillingness comply study protocol requirement ; 19 . Any reason , , accord researcher opinion , impede participation volunteer study ; 20 . Pregnant lactate woman ( woman negative pregnancy test result day screen ) . 1 . Unexpected previously unknown adverse reaction ( related support volunteer 's health ) ; 2 . Occurrence SAEs ; 3 . Acute disease condition SAEs , accord researcher opinion , require exclusion volunteer study ; 4 . Decision volunteer withdraw study ; 5 . Violation volunteer prescribe regimen violation research restriction ( decision investigator ) ; 6 . Investigator 's decision exclude volunteer study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>